Gland Pharma Ltd’s shares rose up to 5% after the company received USFDA approval for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC). The product, equivalent to Alcon’s Pataday Once Daily Relief, is used to treat ocular itching caused by allergic conjunctivitis.